Expert Committees
Composition: The Clinical Guidelines Program works directly with committees composed of experts in the field who represent multiple disciplines (medicine, nursing, psychology, pharmacy, public health, social work, mental health), clinical specialties (infectious diseases, family medicine, obstetrics and gynecology, hepatology, pediatrics, psychiatry, dentistry, prevention, etc.), and various geographic regions of New York State.
A Clinical Guidelines Program Steering Committee provides oversight and strategy to the following Clinical Guidelines Program committees, each of which is responsible for developing and updating clinical practice guidelines that fall under its area of expertise. Current committees (May 2018) include the following:
- Medical Care Criteria Committee (Adult HIV and related guidelines)
- Subcommittee on the Care of Adolescents with HIV
- Hepatitis C Virus Infection Guidelines Committee
- Perinatal Transmission Prevention Guideline Committee
- Sexually Transmitted Infections Guidelines Committee
- Substance Use Guidelines Committee
- Dental Standards of Care Committee
Financial disclosure and confidentiality agreement: All potential and active committee members are required to sign a confidentiality agreement and to disclose annually all financial relationships with commercial entities or gifts that may be actual, potential, or perceived as conflicts of interest. Committee members must report financial relationships with commercial entities that have existed in the 12 months prior to or are expected to exist in the 12 months after the date on which they sign their disclosure form.
Guideline development process: When the Clinical Guidelines Program identifies the need to develop or update a guideline, the committee under whose purview the guideline falls convenes to determine the goals of the guideline and its content, review the published literature, and weigh new evidence for recommendations. Text is then drafted by an author who has experience with the topic of the guideline. The guideline draft is edited by the team at JHU, and then reviewed and modified by the committee. This rigorous development process may entail multiple rounds of review, revision, rating and editing. Decision making occurs by consensus, and all guideline recommendations are reviewed by and receive the consensus approval of the full guideline committee.
Evidence-based Recommendations: All recommendations are rated to reflect the strength of each recommendation and the quality of the supporting evidence. Ratings are reached through review of the evidence and consensus decision. If the published evidence in support of a particular recommendation is not sufficient, the group relies on collective best practices experience to develop a final statement. The rating scheme for recommendations appears below.
| AIDS Institute Clinical Guidelines Program: Recommendations Ratings (updated June 2019 [a]) |
|
| Strength of Recommendation Ratings | |
| A | Strong recommendation |
| B | Moderate recommendation |
| C | Optional |
| Quality of Supporting Evidence Ratings | |
| 1 | Indicates that the evidence supporting a recommendation is derived from published results of at least one randomized trial with clinical outcomes or validated laboratory endpoints. |
| * | Indicates that the evidence supporting a recommendation is strong because it is: 1) based on a self-evident conclusion(s); 2) conclusive, published, in vitro data; or 3) well-established, accepted practice that cannot be tested because ethics would preclude a clinical trial. |
| 2 | Indicates that the evidence supporting a recommendation is derived from published results of at least one well-designed, nonrandomized clinical trial or observational cohort study with long-term clinical outcomes. |
| 2† | Indicates that the evidence supporting a recommendation has been extrapolated from published results of well-designed studies (including non-randomized clinical trials) conducted in populations other than those specifically addressed by a recommendation. The source(s) of the extrapolated evidence and the rationale for the extrapolation are provided in the guideline text. One example would be results of studies conducted predominantly in a subpopulation (e.g., one gender) that the committee determines to be generalizable to the population under consideration in the guideline. |
| 3 | Indicates that a recommendation is based on the expert opinion of the committee members. The rationale for the recommendation is provided in the guideline text. |
|
|
External review: All guidelines are reviewed by external experts in the field and by the AIDS Institute’s Consumer Advisory Committee.
Final approval: The guideline is submitted to the AIDS Institute for review and final approval prior to publication. The AI may request additional review by other agencies and organizations when applicable.
Guideline Updates: Members of guideline committees monitor developments ongoing to maintain guideline currency, at regular intervals. Newly published data that provides support for existing recommendations will be cited in the text and the studies will be added to the reference list. If newly published data prompts a revision to recommendations or rationale, a planning committee proposes appropriate edits and determines whether any changes warrant full committee review and approval.
Medical Care Criteria Committee (MCCC; Adult HIV Treatment and Prevention)
Updated February 2020 | Recent changes to the MCCC
Leadership
Chair: Joseph P. McGowan, MD, FACP, FIDSA
North Shore University Hospital, Manhasset, NY
No disclosures
Vice-Chair: Steven M. Fine, MD, PhD
University of Rochester Medical Center, Rochester, NY
No disclosures
Chair Emeritus: Samuel T. Merrick, MD
New York Presbyterian Hospital-Weill Cornell Medical Center, New York, NY
No disclosures
Medical Director: Charles J. Gonzalez, MD
New York State Department of Health, AIDS Institute, New York, NY
No disclosures
Deputy Medical Director: Lyn C. Stevens, MS, NP, ACRN
New York State Department of Health AIDS Institute, Albany, NY
No disclosures
JHU Principal Investigator: Christopher J. Hoffmann, MD, MPH
Johns Hopkins University School of Medicine, Division of Infectious Diseases, Baltimore, MD
No disclosures
Contributing Members
Jessica M. Atrio, MD, MSc
Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY
No disclosures
James C. M. Brust, MD
Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY
No disclosures
John M. Conry, PharmD, AAHIVP, FNAP
St. John’s University, Queens, NY
No disclosures
Elliot DeHaan, MD
New York Presbyterian Hospital-Weill Cornell Medical Center, New York, NY
No disclosures
Mary Dyer, MD
Hudson River Healthcare, Monticello, NY
No disclosures
Daniel Egan, MD
Columbia University Vagelos College of Physicians and Surgeons, New York, NY
No disclosures
Annette Gaudino, Community Advisor
Treatment Action Group (TAG), New York, NY
No disclosures
Jeremiah Johnson, Community Advisor
Treatment Action Group (TAG), New York, NY
No disclosures
Christine A. Kerr, MD
Galileo Health
No disclosures
Jeremy D. Kidd, MD, MPH
New York Presbyterian Hospital, Columbia University, New York, NY
No disclosures
Gene Morse, PharmD, FCCP, BCPS
University at Buffalo School of Pharmacy & Pharmaceutical Sciences, Buffalo, NY
No disclosures
Hector Ojeda-Martinez, MD
SUNY Downstate Medical Center, Brooklyn, NY
No disclosures
Asa E. Radix, MD, MPH, FACP, AAHIVS
Callen-Lorde Community Health Center, New York, NY
No disclosures
Sanjiv S. Shah, MD, MPH, AAHIVM, AAHIVS
MetroPlus Health Plan, New York, NY
No disclosures
Noga Shalev, MD
Columbia University Medical Center, New York, NY
No disclosures
Eugenia L. Siegler, MD
Weill Cornell Medical College, New York, NY
No disclosures
Maria Teresa (Tess) Timoney, MS, RN, CNM
Bronx Lebanon Hospital Center, Bronx, NY
No disclosures
Marguerite A. Urban, MD
University of Rochester School of Medicine and Dentistry, Rochester, NY
No disclosures
Antonio E. Urbina, MD
The Mount Sinai Hospital, Comprehensive Health Program-Downtown, New York, NY
Scientific Advisor: Gilead, ViiV, Merck
Rona M. Vail, MD
Callen-Lorde Community Health Center, New York, NY
No disclosures
Geoffrey A. Weinberg, MD
University of Rochester School of Medicine and Dentistry, Rochester, NY
No disclosures
Recent Changes to the MCCC
January 2020
Joined the MCCC: Jessica M. Atrio, MD, MSc, Albert Einstein College of Medicine/Montefiore Medical Center; Oni Blackstock, MD, MHS, New York City Department of Health and Mental Hygiene
Stepped down from the MCCC: Julie E. Myers, MD, MPH, New York City Department of Health and Mental Hygiene
December 2019
Stepped down from the MCCC: Jack Fuhrer, MD, Stony Brook University School of Medicine; Luz Amarilis Lugo, MD, Mount Sinai Comprehensive Health Program-Downtown; Cynthia H. Miller, MD, Albany Medical Center; David C. Perlman, MD, Icahn School of Medicine at Mount Sinai
Hepatitis C Virus (HCV) Guideline Committee
Updated February 2020 | Recent changes to the HCV Guideline Committee
Leadership
Chair: Joshua S. Aron, MD
Elmhurst Hospital Center, Elmhurst, NY
No disclosures
Vice Chair: Ponni V. Perumalswami, MD
Icahn School of Medicine at Mount Sinai, New York, NY
No disclosures
Chair Emerita: Christine A. Kerr, MD
Galileo Health
No disclosures
Medical Director: Charles J. Gonzalez, MD
New York State Department of Health AIDS Institute, New York, NY
No disclosures
Deputy Medical Director: Lyn C. Stevens, MS, NP, ACRN
New York State Department of Health AIDS Institute, Albany, NY
No disclosures
JHU Principal Investigator: Christopher J. Hoffmann, MD, MPH
Johns Hopkins University School of Medicine, Division of Infectious Diseases, Baltimore, MD
No disclosures
AIDS Institute Clinical Representative, Viral Hepatitis: Colleen Flanigan, RN, MS
New York State Department of Health AIDS Institute, Albany, NY
No disclosures
Contributing Members
Mary Angerame, MS APN-BC
Jordan Health, Rochester, NY
No disclosures
Ayse Aytaman, MD, AGAF, FACG
Veterans Affairs New York Harbor Healthcare System, Brooklyn, NY
No disclosures
David Bernstein, MD, FAASLD, FACG, AGAF, FACP
Hofstra-Northwell School of Medicine, Manhasset, NY
Scientific Advisor: Abbvie, Gilead
Annette Gaudino, Community Advisor
Treatment Action Group (TAG), New York, NY
No disclosures
Kristen Marks, MD
Weill Cornell Medical College, New York, NY
No disclosures
Brianna Norton, DO, MPH
Montefiore Medical Group, Bronx, NY
No disclosures
Jeffrey J. Weiss, PhD, MS
Mount Sinai School of Medicine, New York, NY
No disclosures
Recent Changes to the HCV Guideline Committee
February 2020
Appointed vice-chair: Ponni V. Perumalswami, MD, Icahn School of Medicine at Mount Sinai
Stepped down as vice-chair; appointed chair emerita: Christine A. Kerr, MD, Galileo Health
Perinatal Transmission Prevention Guideline Committee
Updated February 2020
Leadership
Chair: Marc Foca, MD,
No disclosures
Chair Emeritus: Rodney L. Wright, MD, MS
Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY
No disclosures
Chair Emeritus: Murli Purswani, MBChB, FAAP
Bronx-Lebanon Hospital Center, Bronx, NY
No disclosures
Medical Director: Charles J. Gonzalez, MD
New York State Department of Health AIDS Institute, New York, NY
No disclosures
Deputy Medical Director: Lyn C. Stevens, MS, NP, ACRN
New York State Department of Health AIDS Institute, Albany, NY
No disclosures
JHU Principal Investigator: Christopher J. Hoffmann, MD, MPH
Johns Hopkins University School of Medicine, Division of Infectious Diseases, Baltimore, MD
No disclosures
AIDS Institute Clinical Representative, Perinatal HIV Prevention: Suzanne Kaufman, MPH, BSN, AACRN
New York State Department of Health AIDS Institute, Albany, NY
No disclosures
Contributing Members
Helene Bernstein, MD, PhD
Upstate Medical University, Syracuse, NY
No disclosures
Ara Fernandez, MD, FAAP
Harlem Hospital Center, New York, NY
No disclosures
Annette Gaudino, Community Advisor
Treatment Action Group (TAG), New York, NY
No disclosures
Courtney Olson-Chen, MD
University of Rochester Medical School, Rochester, NY
No disclosures
Maria Teresa (Tess) Timoney, MS, RN, CNM
Bronx Lebanon Hospital Center, Bronx, NY
No disclosures
Geoffrey A. Weinberg, MD
University of Rochester School of Medicine and Dentistry, Rochester, NY
No disclosures
Substance Use Guideline Committee
Updated February 2020
Leadership
Chair: Chinazo O. Cunningham, MD, MS
Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY
No disclosures
Vice Chair: Kelly S. Ramsey, MD, MPH, MA, FACP
Hudson River HealthCare, Poughkeepsie, NY
No disclosures
Medical Director: Charles J. Gonzalez, MD
New York State Department of Health AIDS Institute, New York, NY
No disclosures
Deputy Medical Director: Lyn C. Stevens, MS, NP, ACRN
New York State Department of Health AIDS Institute, Albany, NY
No disclosures
JHU Principal Investigator: Christopher J. Hoffmann, MD, MPH
Johns Hopkins University School of Medicine, Division of Infectious Diseases, Baltimore, MD
No disclosures
AIDS Institute Clinical Representative, Harm Reduction in Healthcare: Sharon L. Stancliff, MD
New York State Department of Health AIDS Institute, New York, NY
No disclosures
AIDS Institute Clinical Representative, Drug User Health: Narelle Ellendon, RN
New York State Department of Health AIDS Institute, New York, NY
No disclosures
Contributing Members
Marcus Bachhuber, MD, MS
Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY
No disclosures
Michael L. Christie, MD
University of Rochester Medical Center, Rochester, NY
No disclosures
Annette Gaudino, Community Advisor
Treatment Action Group (TAG), New York, NY
No disclosures
Angela G. Giovanniello, PharmD, AAHIVP
Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY
No disclosures
Raymond Harvey, MD
Institute for Family Health, Kingston, NY
No disclosures
Giliane Joseph, MD
Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY
No disclosures
Hillary Kunins, MD, MPH, MS, NYC DOHMH, Queens, NY
New York City Department of Health and Mental Hygiene
No disclosures
Shadi Nahvi, MD, MS
Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY
No disclosures
David C. Perlman, MD
Icahn School of Medicine at Mount Sinai, New York, NY
No disclosures
Susan D. Whitley, MD
New York City Health + Hospitals/Kings County, Brooklyn, NY
No disclosures
Timothy J. Wiegand, MD
University of Rochester Medical Center, Rochester, NY
Consultant: McKesson Corporation
Institutional, Agency, and Program Liaison Advisory Group
Updated February 2020
Douglas Fish, MD
Office of Health Insurance Programs
New York State Department of Health, Albany, NY
No disclosures
Marc Manseau, MD
Office of Alcoholism and Substance Abuse Services
New York State Department of Health, Albany, NY
No disclosures
Monica Parker, PhD
Bloodborne Viruses Laboratory, Wadsworth Center
New York State Department of Health, Albany, NY
No disclosures
William M. Valenti, MD, FIDSA, Trillium Health, Rochester, NY
Medical Society of the State of New York
Financial disclosure: Scientific Advisor, Gilead Sciences